RedHill officer Adi Frish files Form 3 holdings
RedHill Biopharma executive Adi Frish filed an initial ownership report showing existing equity interests, not new trades.
Rhea-AI Filing Summary
RedHill Biopharma executive Adi Frish filed an initial ownership report showing existing equity interests, not new trades. He reports 27,681 unvested restricted share units tied to American Depositary Shares, 6,280 ADSs that are convertible at any time, stock options over 250,000, 370,000, 600,000 and 750,000 ordinary shares, and 276,810,000 ordinary shares held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Frish Adi
Role
Chief Corp & BD Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | American Depositary Shares | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
American Depositary Shares — 62,800,000 contracts (Direct);
Stock Option (Right to Buy) — 1,970,000 contracts (Direct);
Ordinary Shares — 276,810,000 shares (Direct)
Footnotes (6)
- F1. Represents 27,681 unvested restricted share units ("RSUs"), each with respect to one American Depositary Share ("ADS"), which represents 10,000 ordinary shares, par value NIS 0.01 per share ("Ordinary Shares"), of RedHill Biopharma Inc. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares.
- F2. Represents 6,280 ADSs, which are convertible at any time, at the holder's election and have no expiration date.
- F3. Represents stock option to purchase 250,000 Ordinary Shares (equivalent to 25 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $5,000 per ADS and the option expires on March 21,2028.
- F4. Represents stock option to purchase 370,000 Ordinary Shares (equivalent to 37 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $5,000 per ADS and the option expires on May 6, 2029.
- F5. Represents stock option to purchase 600,000 Ordinary Shares (equivalent to 60 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $4,870 per ADS and the option expires on March 25, 2030.
- F6. Represents stock option to purchase 750,000 Ordinary Shares (equivalent to 75 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $7,080 per ADS and the option expires on April 28, 2031.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Adi Frish’s Form 3 for RedHill Biopharma (RDHL) show?
The Form 3 reports Adi Frish’s existing equity holdings in RedHill Biopharma, not new trades. It lists restricted share units, American Depositary Shares, fully vested stock options over ordinary shares, and a large direct holding of 276,810,000 ordinary shares as of the filing date.
How many RedHill Biopharma ADSs does Adi Frish report owning on Form 3?
Adi Frish reports 6,280 American Depositary Shares that are convertible at any time and have no expiration date. Each ADS represents underlying ordinary shares of RedHill Biopharma, giving him direct exposure through this ADR structure alongside other equity interests disclosed.
What stock options in RedHill Biopharma does Adi Frish report on Form 3?
He reports fully vested stock options to purchase 250,000, 370,000, 600,000 and 750,000 ordinary shares. Footnotes state these options were issued under the RedHill 2010 Option Plan with exercise prices quoted per ADS and expirations in 2028, 2029, 2030 and 2031 respectively.
Does Adi Frish’s RedHill Biopharma Form 3 show any recent buying or selling?
No buy or sell transactions are indicated; the entry is categorized as holdings with unknown transaction codes. The Form 3 serves as an initial statement of beneficial ownership, summarizing existing positions rather than reporting new market purchases or sales of RedHill securities.
AI-generated analysis. How Rhea-AI works. Not financial advice.
